# mFOLFIRINOX Plus Radiotherapy to Patients With CA19-9-normal Advanced Pancreatic Cancer Refractory to Chemotherapy

Source: https://onco.cc/trials/nct06249321/  
OnCo record `nct06249321` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2 trial in pancreatic cancer, run by Fudan University, now recruiting.

## Summary

mFOLFIRINOX Plus Radiotherapy to Patients With CA19-9-normal Advanced Pancreatic Cancer Refractory to Chemotherapy is a phase 2, interventional study registered as NCT06249321 by Fudan University, with a registry enrolment figure of 30 participants, started 2024-04-01 and due to reach its primary completion in 2026-03-01. Interventions recorded: mFOLFIRINOX plus IMRT. Conditions listed: Pancreatic Cancer; Radiotherapy. Primary outcome: progression-free survival, PFS. Pancreatic eligibility wording from the registry: "* Histologically or cytologically confirmed advanced pancreas adenocarcinoma". Sites: China. No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-24
- Also known as: PTCA199-10
- Tags: ctgov-ingest; pancreatic-deep-dive
- Registry id: NCT06249321
- Phase: 2
- Setting: mFOLFIRINOX Plus Radiotherapy to Patients With CA19-9-normal Advanced Pancreatic Cancer Refractory to Chemotherapy
- Sponsor: Fudan University
- Enrolled: 30

## Sources

- ClinicalTrials.gov NCT06249321: https://clinicaltrials.gov/study/NCT06249321

## Connected records

- cancers: [Metastatic pancreatic ductal adenocarcinoma](https://onco.cc/cancers/metastatic-pdac/)
- technologies: [IMRT / IGRT (modern external beam)](https://onco.cc/technologies/imrt-igrt/)
- terms: [Pancreatic cancer trials open today (registry snapshot and UK sites)](https://onco.cc/terms/pancreatic-trials-open-today/)

---
JSON: https://onco.cc/api/v1/entities/nct06249321.json